Trending menu:
Verona Pharma has reported positive top-line data from a Phase IIb dose-ranging study assessing the efficacy of ensifentrine for the treatment of chronic obstructive pulmonary disease (COPD).
Akero Therapeutics is set to expand the ongoing Phase IIa BALANCED study of Fc-FGF21 fusion protein AKR-001 to include an additional cohort of subjects with non-alcoholic steatohepatitis (NASH) who have...
US-based T cell-based cancer immunotherapies developer Iovance Biotherapeutics and clinical-stage biopharmaceutical firm Cellectis have signed a research collaboration and exclusive worldwide license agreement.
Terns Pharmaceuticals has reported positive results from an ongoing Phase I clinical trial of TERN-201 for the treatment of non-alcoholic steatohepatitis (NASH).
Nektar Therapeutics and Bristol-Myers Squibb Company have entered a revised strategic collaboration agreement to expand the clinical development programme for bempegaldesleukin (bempeg) plus Opdivo (nivolumab).
Zymeworks has initiated a Phase II trial to assess the efficacy of ZW25 as a combination therapy for previously-treated locally advanced and/or metastatic HER2-positive, HR-positive breast cancer.
Life sciences firm Elysium Health has initiated a clinical trial at Duke Clinical Research Institute to study correlations between epigenetic age and circulating nicotinamide adenine dinucleotide (NAD+) levels in healthy...
ADC Therapeutics has reported positive results from the Phase II clinical trial of loncastuximab tesirine (ADCT-402) for treating relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
Gemini Therapeutics has commenced patient enrolment in its Phase I study of GEM103 for the treatment of dry age-related macular degeneration (AMD).
Regeneron Pharmaceuticals has reported positive results from the LUMINA-1 trial of garetosmab (REGN2477) for fibrodysplasia ossificans progressiva (FOP), a very rare bone disease.
